Samantha Truex officially unwraps Upstream Bio, her secretive, OrbiMed-backed biotech with $200M in the bank
After Samantha Truex shut down Quench Bio early last year, she knew she wanted to get back into the biotech world and run another company. The path just ended up more winding than initially expected.
Truex had joined Atlas Ventures a couple months after Quench closed up shop, and the wheels were in motion for her to run an Atlas-backed company late last year, as Endpoints News previously reported in February. But she soon decided to change course and joined an OrbiMed-funded biotech still in stealth, one that had raised $200 million, with records listing her as CEO as early as Nov. 30, 2021.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.